Avacen’s medical device designed to treat joint pain from arthritis recently received licensing from Health Canada to use the device for treating fibromyalgia.
The Avacen 100 Class II medical device was previously licensed to treat joint pain that comes with arthritis for a drug-free muscle relaxer. Before the device’s new licensing, the only way to treat fibromyalgia pain was using drugs like Lyrica, Cymbalta or Savella.
Fibromyalgia is a chronic pain disorder that causes someone to have widespread pain and tenderness to touch over the body. About 10 million Americans have fibromyalgia and it occurs in people of all ages, according to the National Fibromyalgia and Chronic Pain Association. There is currently no cure for the disorder, but there are new approaches to pain management and symptom relief that are shining new light on fibromyalgia.
Avacen 100 uses an Avacen treatment method to treat pain associated with fibromyalgia and also recently received CE Mark to market in Europe where some prescription medications have been rejected by regulatory offices.
The treatment is non-invasive and safely infuses heat into the circulatory system to relax muscles and increase microcirculation in the body. While other devices focus on localized pain relief, Avacen 100 provides widespread relief.
A study testing the efficiency of Avacen 100 showed the there was 100% positive results for a full therapeutic treatment group.The study included 22 people who had fibromyalgia and a 28-day follow-up study revealed that there was a reduction of widespread pain of over 40% and a reduction in the average tender touch points from 15 to 9.